Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | MGAM | O43451 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | SI | P14410 | 1/20 | 0.37 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.32 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15085751 | 0.84 | TSHR (0.39) | TSHRHSD17B10MGAMGAASI | |
| SCHEMBL12616651 | 0.84 | TSHR (0.34) | TSHRHSD17B10MGAMGAASI | |
| SCHEMBL24414202 | 0.83 | TSHR (0.37) | TSHRHSD17B10MGAMGAASI | |
| SCHEMBL1935839 | 0.79 | TSHR (0.34) | TSHRHSD17B10MGAMGAASI | |
| SCHEMBL9937614 | 0.79 | HTT (0.48) | TSHRHSD17B10HTTALDH1A1MEN1 | |
| SCHEMBL7751888 | 0.79 | TSHR (0.42) | TSHRHSD17B10MGAMGAASI | |
| SCHEMBL9937723 | 0.78 | GAA (0.44) | TSHRHSD17B10MGAMGAASI | |
| SCHEMBL5856166 | 0.78 | PSEN1 (0.35) | HTTALDH1A1PLA2G2C | |
| SCHEMBL9937397 | 0.78 | HTT (0.35) | TSHRHTTALDH1A1MEN1CYP3A4 | |
| SCHEMBL15297220 | 0.77 | CES2 (0.47) | TSHRHSD17B10MGAMGAASI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3555080-B1 | OXAZINE DERIVATIVES AS BETA-SECRETASE INHIBITORS AND METHODS OF USE | AMGEN INC (US) | 2023-09-20 | — | — | EP | disclosed |
| EP-3555080-B1 | OXAZINE DERIVATIVES AS BETA-SECRETASE INHIBITORS AND METHODS OF USE | AMGEN INC (US) | 2023-09-20 | — | — | EP | disclosed |
| US-10947223-B2 | Substituted oxazines as beta-secretase inhibitors | AMGEN INC. (US) | 2021-03-16 | — | — | US | disclosed |
| US-10947223-B2 | Substituted oxazines as beta-secretase inhibitors | AMGEN INC. (US) | 2021-03-16 | — | — | US | disclosed |
| US-20200207747-A1 | OXAZINE DERIVATIVES AS BETA-SECRETASE INHIBITORS AND METHODS OF USE | AMGEN INC. (US) | 2020-07-02 | — | — | US | disclosed |
| US-20200207747-A1 | OXAZINE DERIVATIVES AS BETA-SECRETASE INHIBITORS AND METHODS OF USE | AMGEN INC. (US) | 2020-07-02 | — | — | US | disclosed |
| EP-3555080-A1 | OXAZINE DERIVATIVES AS BETA-SECRETASE INHIBITORS AND METHODS OF USE | Amgen Inc. (US) | 2019-10-23 | — | — | EP | disclosed |
| WO-2018112081-A1 | OXAZINE DERIVATIVES AS BETA-SECRETASE INHIBITORS AND METHODS OF USE | AMGEN INC. (US) | 2018-06-21 | — | — | WO | disclosed |
| WO-2018112081-A1 | OXAZINE DERIVATIVES AS BETA-SECRETASE INHIBITORS AND METHODS OF USE | AMGEN INC. (US) | 2018-06-21 | — | — | WO | disclosed |
| US-9472813-B2 | Battery electrolyte solution containing certain ester-based solvents, and batteries containing such an electrolyte solution | DOW GLOBAL TECHNOLOGIES LLC (US) | 2016-10-18 | — | — | US | disclosed |
| CN-103262329-A | Battery electrolyte solution containing certain ester-based solvents and battery containing such electrolyte solution | DOW GLOBAL TECHNOLOGIES INC | 2013-08-21 | — | — | CN | disclosed |
| WO-2012085501-A1 | 8 - SULFO - IMIDAZOTETRAZIN- 4 - ONE COMPOUNDS AND THEIR USE AS ANTICANCER DRUG | PHARMINOX LIMITED (GB) | 2012-06-28 | — | — | WO | disclosed |
| WO-2012082760-A1 | BATTERY ELECTROLYTE SOLUTION CONTAINING CERTAIN ESTER-BASED SOLVENTS, AND BATTERIES CONTAINING SUCH AN ELECTROLYTE SOLUTION | DOW GLOBAL TECHNOLOGIES LLC (US) | 2012-06-21 | — | — | WO | disclosed |
| US-8067625-B2 | Fluorosurfactants | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-11-29 | — | — | US | disclosed |
| US-8049022-B2 | Fluorosurfactants | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-11-01 | — | — | US | disclosed |
| US-20090264525-A1 | FLUOROSURFACTANTS | MERCK PATENT GMBH (DE) | 2009-10-22 | — | — | US | disclosed |
| EP-0532178-B1 | Methanoanthracenes as dopamine antagonists | ZENECA LTD (GB) | 1996-10-16 | — | — | EP | disclosed |
| US-5455246-A | Treating neuropsychiatric disorders | IMPERIAL CHEMICAL INDUSTRIES, PLC (GB) | 1995-10-03 | — | — | US | disclosed |
| US-5266570-A | Neuropsychiatric disorders | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-11-30 | — | — | US | disclosed |
| EP-0532178-A1 | Methanoanthracenes as dopamine antagonists | ZENECA LIMITED (GB) | 1993-03-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200207747-A1 | OXAZINE DERIVATIVES AS BETA-SECRETASE INHIBITORS AND METHODS OF USE | BACE1, BACE2, APP | TSHR 3673/4885HSD17B10 695/4885MGAM 674/4885 |
| US-20090264525-A1 | FLUOROSURFACTANTS | FASN, FFAR3, SGMS2 | TSHR 754/4885HSD17B10 605/4885MGAM 4205/4885 |
| US-10947223-B2 | Substituted oxazines as beta-secretase inhibitors | BACE1, BACE2, APP | TSHR 3817/4885HSD17B10 852/4885MGAM 1018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.